The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26218264 |
24 |
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
Astex Pharmaceuticals |
| 26181851 |
26 |
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. |
Novartis Institutes For Biomedical Research |
| 25695766 |
43 |
The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity. |
Ensemble Therapeutics |
| 25584393 |
14 |
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity. |
Bristol-Myers Squibb Research |
| 25278234 |
25 |
Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists. |
Bristol-Myers Squibb Research & Development |
| 24631189 |
86 |
Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors. |
Astrazeneca |
| 23651223 |
61 |
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. |
University Of Michigan |
| 23062821 |
51 |
Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. |
Fondazione Irccs Istituto Nazionale Dei Tumori |
| 22148838 |
125 |
Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. |
University Of Michigan |
| 21443232 |
24 |
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
University Of Michigan |
| 22413863 |
21 |
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). |
Genentech |
| 22342627 |
36 |
Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents. |
Cisi |
| 22264476 |
60 |
Discovery of aminopiperidine-based Smac mimetics as IAP antagonists. |
Astrazeneca R&D Boston |
| 21462933 |
155 |
Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. |
University Of Michigan |
| 20684551 |
40 |
Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. |
University Of Michigan |
| 20443226 |
15 |
Cyclopeptide Smac mimetics as antagonists of IAP proteins. |
University Of Michigan |
| 19138149 |
15 |
Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. |
Chinese Academy Of Sciences |
| 19049347 |
12 |
Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. |
University Of Michigan |
| 18313309 |
13 |
Degradation-promoters of cellular inhibitor of apoptosis protein 1 based on bestatin and actinonin. |
The University Of Tokyo |
| 28434765 |
6 |
4-Connected azabicyclo[5.3.0]decane Smac mimetics-Zn |
Istituto Di Scienze E Tecnologie Molecolari (Istm) |
| 28492317 |
35 |
Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP). |
Astex Pharmaceuticals |
| 23402383 |
6 |
Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. |
Msa University |
| 18819811 |
195 |
Carbonic anhydrase inhibitors: synthesis and inhibition studies against mammalian isoforms I-XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. |
Istanbul University |
Search and Browse
